Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Inquiry

The legacy of general health and science information has long served as a foundational resource for public understanding of medical conditions and therapeutic interventions. Within this broad domain, the dissemination of knowledge regarding bone health, metabolic disorders, and pharmaceutical treatments has been a central focus. This heritage includes the communication of research findings, clinical guidelines, and safety profiles associated with widely prescribed medications. As the landscape of medical inquiry evolves, the need to translate general health principles into specific, context-driven investigations becomes increasingly apparent. One such area of focused concern arises from the intersection of pharmaceutical exposure and adverse tissue responses. The transition from broad health education to a more targeted examination of occupational or patient-specific risk factors is a natural progression. In this context, the discussion pivots from general awareness of medication side effects to a concentrated inquiry into the potential relationship between bisphosphonate therapy, specifically Fosamax, and the development of osteonecrosis of the jaw. This shift necessitates a careful consideration of exposure parameters, patient history, and clinical presentation, moving beyond general health narratives to address a discrete, clinically significant outcome. The following analysis will explore this specific causation question without delving into mechanistic pathways.

Fosamax and Osteonecrosis of the Jaw: An Overview

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously or following dental procedures. Clinical presentation typically involves pain, swelling, infection, and delayed healing after tooth extraction or other oral surgery. The condition can be diagnosed through clinical examination and imaging, though definitive diagnosis often requires exclusion of other causes such as malignancy or infection. Multiscale characterization of jawbone tissue has provided insights into the unique responses of the jaw to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). The association between Fosamax and ONJ is supported by evidence from FDA-approved labeling. The prescribing information states that ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Risk Factors and Clinical Considerations

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure, and for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are thought to involve suppression of bone turnover, leading to impaired remodeling and repair of microdamage in the jawbone. Bisphosphonates accumulate in bone, particularly at sites of high turnover, and their long half-life may contribute to prolonged suppression of osteoclast activity. This can result in reduced blood supply, increased susceptibility to infection, and delayed healing after dental trauma. The jawbone's unique anatomy and high remodeling rate may make it particularly vulnerable to these effects. Regarding the timeline between exposure and documented harm, the time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, though a subset may have recurrence if rechallenged with the same or another bisphosphonate. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials was low and not significantly different from placebo, indicating that other factors, such as underlying dental disease or procedures, may play a critical role.

Adequacy of Warnings and Causation Considerations

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information, which includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions.' The labeling advises discontinuation of Fosamax if severe symptoms develop and notes that most patients have relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also identifies known risk factors and recommends that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, causation considerations involve evaluating the temporal relationship between Fosamax exposure and ONJ onset, as well as the presence of other risk factors such as dental procedures, cancer, or concomitant medications. While Fosamax is associated with ONJ, it is not the sole cause, and many cases occur in patients with additional predisposing conditions. The evidence supports that Fosamax can contribute to the development of ONJ, particularly in the presence of other risk factors, but the overall risk is low and must be weighed against the benefits of fracture prevention.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. It is approved for postmenopausal women, men with osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the jaw, often occurring spontaneously or after dental procedures. Symptoms include pain, swelling, infection, and delayed healing. Diagnosis is based on clinical examination and imaging, excluding other causes like malignancy or infection (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Does Fosamax cause osteonecrosis of the jaw?

Fosamax is associated with an increased risk of ONJ, as stated in its prescribing information. However, the risk is low and often involves other factors such as dental procedures, cancer, or concomitant medications. The FDA labeling includes warnings and recommends discontinuation if severe symptoms occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Longer duration of bisphosphonate use may increase risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.